Erbi Biosystems Raises $ 4 Million to Supply Small-Scale Infusion Bioreactors for Cell Therapy Development and Manufacturing

Manufacturers of the only commercially available ml-scale bioreactor with fully automated True Perfusion â„¢ capability, secured additional funding to expand its cell therapy development and manufacturing solutions

CAMBRIDGE, Mass., January 4, 2022 / PRNewswire / – Erbi Biosystems, developer of innovative, small-scale, automated and high-performance cell culture systems, has closed a round of private funding totaling $ 4 million. This latest funding will allow the company to expand its operations to meet growing demand for its Breez infusion bioreactor product and develop extensions to improve cell therapy applications.

The Erbi Breez bioreactor provides continuous medium addition, cell retention and bubble-free gas diffusion through its True Perfusion technology, which is unique among existing small-scale bioreactors that can only approximate perfusion with exchange of intermittent medium. The Breez’s fully automated, sterile, single-use system also includes online detection and controls that are combined with easy-to-use software, delivering sophisticated feeding strategies, cell concentration and media exchanges, resulting in performance that can exceed the stirred tank and the bag reactor tilting.

“Erbi has developed a compelling platform for small-scale cell culture,” said Michael chambers, investor in Erbi and founding CEO of Aldevron. “In addition to its bioprocessing capabilities, their platform allows testing of multiple replicates from a single sample of cells from rare patients – a unique and potent ability that will accelerate the development of cell therapy. “

“The Breez product has been shown to be an effective tool for the development of processes in a range of cell types,” said Dr. Martin madaus, former President and CEO of Millipore. “The small-volume, single-use, sterile and fully automated format makes it an ideal platform for the manufacture of cell therapy. “

In 2021, Erbi Biosystems doubled its workforce and moved to a larger facility north of Cambridge, equipped with biolabs and cleanroom manufacturing space.

The story continues

“We are growing rapidly and plan to double again in 2022,” said Dr. Michael chiu, CEO of Erbi Biosystems. “The income from our growing list of Breez clients in the United States, Europe and Asia fuel our growth. This additional funding allows us to accelerate our pipeline of technology and product development projects focused on the needs of cell therapy process development and GMP manufacturing. “

Both Mr. Chambers and Dr. Madaus are investors in the latest private round.

About Erbi Biosystems

Erbi Biosystems supports manufacturers of therapeutic drugs with tools to accelerate the development of their processes and therapies. Erbi’s technology platform includes ml-scale single-use cell culture, microfluidics, optical detection and integrated controls.

The Breez bioreactor is used in a range of applications and cell types, including the development of media and cell lines; intensified process and n-1; CAR-T process development; and culturing non-mammalian cells. The small, single-use device and fully automated operation dramatically reduce the time, media consumption, and lab space required for process development. The ml-scale working volume and closed sterile consumable format make it ideal for working with rare and highly variable source materials, such as the development of autologous therapies.

The Erbi Breez system is available worldwide with sales and distribution in the US, EU and China.

Show original content:https://www.prnewswire.com/news-releases/erbi-biosystems-raises-4m-to-provide-small-scale-perfusion-bioreactors-for-development-and-manufacture-of-cell-therapies-301453179. html

SOURCE Erbi Biosystems